CAR Chase: Where Do Engineered Cells Go in Humans?

Chimeric antigen receptor (CAR) – and T-cell receptor (TCR) – modified T-cells are rapidly emerging as a viable treatment option for cancer patients. While initial clinical trials for these CAR T cells showed response rates of over 90% in some cases, retrospective studies have revealed a wide variab...

Descripción completa

Detalles Bibliográficos
Autores principales: Krebs, Simone, Dacek, Megan M., Carter, Lukas M., Scheinberg, David A., Larson, Steven M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7518311/
https://www.ncbi.nlm.nih.gov/pubmed/33042849
http://dx.doi.org/10.3389/fonc.2020.577773

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7518311/
https://www.ncbi.nlm.nih.gov/pubmed/33042849
http://dx.doi.org/10.3389/fonc.2020.577773

Ejemplares similares